- Antares Pharma Inc.’s QuickShot Testosterone (XYOSTED) is awaiting Phase 3 approval by the FDA for treatment of low testosterone levels associated with hypogonadism.

- On the 12th of October, the company announced that it had received notice from the FDA which identified deficiencies that will prevent the drug from moving forward.

- Here I evaluate Antares' prospects.

Guest post by Jennifer Chin. The views and opinions expressed in this article are those of the author and do not necessarily reflect the position of Integer Investments.

To read the full article click here.

#Stocks #stockmarket #antarespharma